

In May 2023, Amgen launched the KANJINTI® 420 mg multiple-dose vial kit (NDC 55513-0164-01). The KANJINTI® 420 mg multiple-dose vial kit contains one multiple-dose vial of KANJINTI® 420 mg and one 20 ml vial of BWFI.

In September 2023, Amgen provided notification to its trading partners that KANJINTI® 420 mg multiple-dose vial (NDC 55513-0132-01) would be temporarily unavailable. To minimize disruption to customers, Amgen has worked with contracted wholesalers to substitute orders of KANJINTI® 420 mg multiple-dose vial (NDC 55513-0132-01) with KANJINTI® 420 mg multiple-dose vial kit (NDC 55513-0164-01). Amgen will notify its trading partners thirty (30) days prior to the reinstatement of the KANJINTI® 420 mg multi-dose vial, and at that time will also provide an updated notice regarding 340B.

340B Inventory Replenishment:

Because the new NDCs are the same product (drug, dose, formulation, or volume) with the same 340B price as the corresponding NDCs, Amgen believes that a covered entity utilizing a 340B inventory replenishment model may count accumulations of the KANJINTI® 420 mg multiple-dose vial toward replenishment of equal quantities of the corresponding KANJINTI® 420 mg multiple-dose vial kit (see table below).

Any questions regarding this matter can be directed to 340Brelations@amgen.com.

NDC	Product	Description
55513-0132-01	KANJINTI® 420 mg multi-dose vial	420 mg multi-dose vial
55513-0164-01	KANJINTI® 420 mg multi-dose vial kit	420 mg multi-dose vial + bwFI diluent